为什么规模越大越有利于控制肿瘤支出:它可能带来较少的竞争，但对循证途径倡议来说可能是一个福音。

Biotechnology healthcare Pub Date : 2011-01-01

John Carroll

{"title":"为什么规模越大越有利于控制肿瘤支出:它可能带来较少的竞争，但对循证途径倡议来说可能是一个福音。","authors":"John Carroll","doi":"","DOIUrl":null,"url":null,"abstract":"Oncology practices nationwide face rising maintenance costs and lower reimbursements for biologic therapies. It's even tougher for small community-based practices, which often lag in adopting new standards of cancer care. Group purchasing organizations claim they have the market clout that oncologists need, and McKesson is betting that they are right. Will the US Oncology buyout deliver?","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 1","pages":"17-21"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086127/pdf/bth08_1p017.pdf","citationCount":"0","resultStr":"{\"title\":\"Why Bigger Is Better For Controlling Oncology Spend: It offers less competition - perhaps - but can be a boon for evidence-based pathway initiatives.\",\"authors\":\"John Carroll\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Oncology practices nationwide face rising maintenance costs and lower reimbursements for biologic therapies. It's even tougher for small community-based practices, which often lag in adopting new standards of cancer care. Group purchasing organizations claim they have the market clout that oncologists need, and McKesson is betting that they are right. Will the US Oncology buyout deliver?\",\"PeriodicalId\":89534,\"journal\":{\"name\":\"Biotechnology healthcare\",\"volume\":\"8 1\",\"pages\":\"17-21\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086127/pdf/bth08_1p017.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biotechnology healthcare\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology healthcare","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

全国范围内的肿瘤学实践面临着维持成本上升和生物疗法报销减少的问题。对于以社区为基础的小型诊所来说，情况更加艰难，它们在采用新的癌症治疗标准方面往往滞后。团购组织声称他们拥有肿瘤学家需要的市场影响力，麦克森认为他们是对的。收购美国肿瘤公司会成功吗?

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

Why Bigger Is Better For Controlling Oncology Spend: It offers less competition - perhaps - but can be a boon for evidence-based pathway initiatives.

Oncology practices nationwide face rising maintenance costs and lower reimbursements for biologic therapies. It's even tougher for small community-based practices, which often lag in adopting new standards of cancer care. Group purchasing organizations claim they have the market clout that oncologists need, and McKesson is betting that they are right. Will the US Oncology buyout deliver?

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biotechnology healthcare

自引率

0.00%

发文量